Glass House Brands (GLAS) Return on Capital Employed (2021 - 2026)
Glass House Brands' (GLAS) quarterly Return on Capital Employed came in at 9.86% in Q1 2026, down 230.81% on a QoQ basis from 2.98% in Q4 2025.
Glass House Brands (GLAS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 6 years of Return on Capital Employed data on file, last reported at 9.86% in Q1 2026.
- On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 9.86% in Q1 2026; TTM through Mar 2026 was 9.86%, a N/A change from a year earlier, with the FY2025 full-year figure at 5.98%, down 836.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 9.86%, down from 2.98% in the prior quarter.
- Over the last five years, Return on Capital Employed for GLAS reached as high as 1.47% in Q3 2022 and fell as low as 12103584.02% in Q1 2022.
- Historically, Return on Capital Employed has averaged 1272629.15% across 5 years, with a median of 11.32% in 2022.
- On a YoY basis, Return on Capital Employed climbed as much as 1237742995 bps in 2022 and fell as far as 444047998 bps in 2022.
- Year by year, Return on Capital Employed stood at 11.32% in 2022, then sank by 83 bps to 20.74% in 2023, then jumped by 56 bps to 9.16% in 2024, then jumped by 67 bps to 2.98% in 2025, then sank by 231 bps to 9.86% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 9.86% in Q1 2026, 2.98% in Q4 2025, and 8.47% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 21.43% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 5.24% |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -9.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86% |
| Dec 31, 2025 | -2.98% |
| Sep 30, 2025 | -8.47% |
| Jun 30, 2025 | -3.09% |
| Jun 30, 2024 | -9.16% |
| Dec 31, 2023 | -20.74% |
| Sep 30, 2023 | -11.98% |
| Jun 30, 2023 | -18.50% |
| Mar 31, 2023 | -16.05% |
| Dec 31, 2022 | -11.32% |
| Sep 30, 2022 | -1.47% |
| Jun 30, 2022 | -4,440,481.32% |
| Mar 31, 2022 | -12,103,584.02% |
| Dec 31, 2021 | -12,377,441.26% |
| Sep 30, 2021 | -5,574,723.75% |
| Jun 30, 2021 | -1.34% |